Introduction
============

Galectin-3 binds and cross-links β-galactoside-containing glycoconjugates ([@B1]--[@B4]). This leads to many of its cellular activities such as directing intracellular traffic of glycoproteins ([@B5]), induction of signaling at the cell surface ([@B1]), or modulation of cell adhesion ([@B6]), which in turn underlies many of the proposed roles of galectin-3 in inflammation, immunity, and cancer. The ligand binding is conferred by the C-terminal canonical galectin carbohydrate recognition domain (CRD)[^3^](#FN3){ref-type="fn"} of about 135 amino acids, and the cross-linking in most cases requires the noncarbohydrate-binding N-terminal domains. The mechanism for this still remains unclear despite many studies. Galectin-3 occurs as a monomer in solution ([@B7]), and cross-linking only occurs upon encounter with certain ligands, which appear to have to be at least divalent ([@B8]--[@B10]). Most studies suggest that the cross-linking is mediated by interaction between the N-terminal domains of one galectin-3 molecule with those in another ([Fig. 1](#F1){ref-type="fig"}*A*); in one case, the composition of its precipitates with a divalent saccharide suggested formation of galectin-3 pentamers ([@B8]), and this is how galectin-3 is depicted in many recent reviews ([@B1]--[@B3]). A few studies have also suggested interaction between CRDs of galectin-3 ([@B11], [@B12]).

![**Two modes of galectin-3 self-association.** The CRD is *filled* with a notch for the carbohydrate-binding site, the N-terminal domains are *open*, and a glycoprotein ligand is *gray* with glycans symbolized by *arrows*. In the common view, named type-N self-association here, the carbohydrate recognition sites remain free to interact with glycoconjugate ligands, and the N-domains of one galectin-3 bind the N-domains of another, forming dimers or higher oligomers, *e.g.* pentamers ([@B8]). In the view indicated by experiments here, named type-C self-association, the carbohydrate recognition site of one galectin-3 binds another site on the CRD of another galectin-3 molecule to form dimers or oligomers. The N-terminal domains are not required, but enhance the interaction. Efficient type-C self-association requires initiation (or nucleation) by interaction with *e.g.* a glycoprotein such as ASF.](zbc0281213070001){#F1}

In all cases, galectin-3 self-association has only been demonstrated at surfaces, artificial or natural, in precipitates, or by chemical cross-linking ([@B8]--[@B15]), which has made detailed quantitative analysis difficult. We have now analyzed galectin-3-ligand interaction in solution, using a fluorescence anisotropy assay, recently applied to interaction between galectin-1 with asialofetuin (ASF) ([@B16]). Surprisingly, the results with galectin-3 appear very different from the case with galectin-1 and are not consistent with the model in [Fig. 1](#F1){ref-type="fig"}*A*. Instead they indicate that ASF binding nucleates self-association of galectin-3 to form oligomers mediated by its carbohydrate recognition site ([Fig. 1](#F1){ref-type="fig"}*B*).

EXPERIMENTAL PROCEDURES
=======================

Materials
---------

Chemicals including fluorescent probes, ASF, and galectin-1 and -3 and galectin-3 mutants were as described before ([@B17]), unless stated otherwise. Lacto*-N*-neohexaose (LNnH) was from Dextra Inc. Redding, UK ([@B16], [@B17]).

Assays
------

### 

#### Fluorescence Anisotropy

The interaction of galectin-3 and mutants with the different ligands was analyzed by a fluorescence anisotropy assay with calculations as described before ([@B16], [@B17]). A new more sensitive plate reader, PHERAstar with software Mars version 2.10 R3 (BMG LABTECH, Offenburg, Germany), was also used.

#### Turbidity

Absorbance spectra (350--800 nm) were acquired on the same samples using the same instrument.

#### Dynamic Light Scattering

Dynamic light scattering was as described before for galectin-1 ([@B16]).

#### Fluorescence Microscopy

Fluorescence microscopy of galectin-3 cell binding and uptake was done as described in Ref. [@B18].

RESULTS
=======

Galectin-3 interaction with ligands was analyzed by three methods. Fluorescence anisotropy of a galectin binding probe was used to measure occupancy of the galectin-3 carbohydrate-binding site, turbidity was used to measure the amount of galectin-3-ligand precipitates, and dynamic light scattering (DLS) was used to measure particle size. Galectin-3 itself is known to behave mainly as a monomer up to about 100 μ[m]{.smallcaps} ([@B7]), and here this was confirmed by the instant observation of solution equilibrium by DLS ([supplemental Fig. S1](http://www.jbc.org/cgi/content/full/C112.358002/DC1)), which also revealed the possible formation of small amounts of dimer (∼4%) at the highest concentration tested (150 μ[m]{.smallcaps}). Other larger aggregates were \<0.1%. Galectin-3C also behaved as a monomer and showed no sign of dimerization by itself.

### 

#### Occupancy of Galectin-3 Carbohydrate-binding Site

First, fixed low concentrations of galectin and fluorescein-tagged probe were mixed with a range of concentrations of ligand as inhibitor, fluorescence anisotropy was measured for each data point, and inhibition curves were calculated ([Fig. 2](#F2){ref-type="fig"}*A*). This showed that ASF inhibited galectin-3 with a potency equivalent to a monovalent ligand with an affinity of *K~d~* ∼6 μ[m]{.smallcaps} or, for example, a nonavalent ligand (as suggested ([@B19])) with an affinity of 54 μ[m]{.smallcaps} for each binding site.

Next, to determine the number of binding sites, we analyzed fixed concentrations of probe and ASF with increasing concentrations of galectin. With only the probe (0.1 μ[m]{.smallcaps}), a curve is obtained going from the anisotropy of the free probe (∼30 mA normalized to 0% bound probe in [Fig. 2](#F2){ref-type="fig"}*B*) to the anisotropy of the probe galectin complex as the excess galectin saturates all probe (165 mA normalized to 100% in [Fig. 2](#F2){ref-type="fig"}*B*). Because the probe itself is present in only trace amounts, this curve can be used as a standard curve to estimate the concentration of free galectin. With inhibitor that binds some of the galectin, the concentration of free galectin will decrease, and the curve will shift to the right, but with enough added galectin, it will still reach 100% if binding sites on the inhibitor are approaching saturation, and therefore free galectin is increasing enough to saturate the probe as well. This is exemplified with the theoretically constructed curves in [Fig. 2](#F2){ref-type="fig"}*B* that assume one or nine binding sites per ASF, respectively (*broken lines*). This was the case with galectin-1, and the curve was even steeper because the galectin-1-binding sites on ASF have a range of affinities, with the weakest binding last ([@B16]). With galectin-3 and ASF, however, after initially following the theoretical curve, data points ([Fig. 2](#F2){ref-type="fig"}*B*, *unfilled squares*) followed a lower slope with increasing galectin, and 100% probe binding was not reached even at the highest galectin concentration. This showed that the concentration of free galectin remained low, in fact lower even than predicted if there were a large excess of saturable binding sites (90 per ASF molecule) ([supplemental Fig. S2](http://www.jbc.org/cgi/content/full/C112.358002/DC1)). This shows that more and more galectin-3, in excess of the theoretically predicted amount, bound ASF without sign of reaching saturation.

![**Analysis of galectin-3 and -1 interaction with ligands (ASF and saccharides) by fluorescence anisotropy.** *A*, decreasing binding (shown as percentage on *y* axis) to A-tetra probe (0.1 μ[m]{.smallcaps}) by galectin-3 (1 μ[m]{.smallcaps}) in the presence of increasing concentrations of ASF (*x* axis). *B*, binding (shown as percentage on *y* axis) of fluorescent A-tetra probe (0.1 μ[m]{.smallcaps}) in the presence of increasing concentrations of galectin-3 (*x* axis) without (*filled circles*) or with 20 μ[m]{.smallcaps} ASF as inhibitor (*unfilled squares*). Theoretically calculated binding curves are shown for no inhibitor (*unbroken line*) or 20 μ[m]{.smallcaps} inhibitor of *K~d~* 6 μ[m]{.smallcaps} or 180 μ[m]{.smallcaps} inhibitor of *K~d~* 54 μ[m]{.smallcaps} (*broken lines*). *C--J*, calculated concentrations of free (*unfilled squares*) and ligand-bound (*filled symbols* and *unbroken lines*) galectin (shown in μ[m]{.smallcaps} on *y* axes). The concentration of free galectin was obtained from experiments as in [Fig. 1](#F1){ref-type="fig"}*B*, using the probe binding curve without ligand as a standard and bound galectin = total − free galectin. To demonstrate reproducibility and consistency, the data of *panels C--J* are from multiple experiments with different probes of different affinities for galectin-3 (*filled circles* for A-tetra probe, *X* for Fucα1-2Galβ1-4Glc (FucLac) probe, and *triangles* for Lac-probe). The experimental data for galectin-1 (*panel D*) are from Salomonsson *et al.* ([@B16]). Theoretical binding curves are shown as *broken lines*, assuming nine binding sites per ASF-molecule of *K~d~* 54 μ[m]{.smallcaps} for galectin-3 and galectin-3C, 1600 μ[m]{.smallcaps} for galectin-3 R186S, 36 μ[m]{.smallcaps} for galectin-1, two binding sites per LNnH molecule of *K~d~* 20 μ[m]{.smallcaps}, and one binding site per LacNAc of *K~d~* 100 μ[m]{.smallcaps} for galectin-3. The *shaded area* is the excess bound galectin-3 as compared with the theoretically calculated curve.](zbc0281213070002){#F2}

To analyze how much galectin-3 could be engaged by one ASF molecule, we calculated the concentration of bound galectin-3 (total minus free as determined by probe saturation) ([Fig. 2](#F2){ref-type="fig"}*C*, *filled symbols*) and compared it with the theoretically calculated curves for nine binding sites per ASF molecule (*broken line*). The excess of bound galectin-3 could now be visualized directly (*gray shaded*) ([Fig. 2](#F2){ref-type="fig"}*C*), and free galectin-3 (*unfilled squares*) remained low (∼5 μ[m]{.smallcaps}) even with very high galectin-3 concentrations. This is in striking contrast to galectin-1 ([Fig. 2](#F2){ref-type="fig"}*D*) where the binding is below the theoretical curve due to decreasing affinity of its binding sites on ASF ([@B16]), and free galectin-1 increases rapidly with higher galectin-1 concentration as ASF becomes saturated.

We also used lower concentrations of ASF to increase the ratio of galectin-3/ASF. Bound galectin-3 increased linearly, without sign of saturation, and at the highest galectin-3 concentration tested, it reached on average about 9 and 25 molecules per ASF molecule when analyzed with 20 and 4 μ[m]{.smallcaps} ASF, respectively ([Fig. 2](#F2){ref-type="fig"}, *C* and *E*) and even as high as on average 75 molecules with 0.8 μ[m]{.smallcaps} ASF ([Fig. 2](#F2){ref-type="fig"}*F*), although data varied more (range 25--125), as described in the legend for [supplemental Fig. S2](http://www.jbc.org/cgi/content/full/C112.358002/DC1).

Apparently, ASF can engage the carbohydrate recognition site of far more galectin-3 molecules than its theoretical number of glycan-based binding sites. A possible explanation is that ASF induces nucleation of galectin-3 oligomers, where the carbohydrate recognition site of one molecule binds another site on the next ([Fig. 1](#F1){ref-type="fig"}*B*). The data are consistent with the theory of protein multimers ([@B20]), where multimer formation is initiated at a certain threshold concentration (nucleation) and free monomer approaches a fixed value. This value is near the *K~d~* of the monomer-monomer interaction, but also depends on the number of nucleation sites ([@B20]). We will refer to this mode of galectin-3 self-association as type-C, because it engages the carbohydrate recognition site ([Fig. 1](#F1){ref-type="fig"}*B*), to distinguish it from the previously proposed modes that leave the carbohydrate-binding site free to interact with ligand and are mediated mainly by the N-terminal domains ([@B8]--[@B10], [@B14]), which we will refer to as type-N ([Fig. 1](#F1){ref-type="fig"}*A*).

#### Formation of Precipitates

As expected, precipitates were formed within seconds at higher galectin-3 concentrations with ASF ([@B8]) and were quantitated by light absorption at 350 nm. With a fixed concentration of galectin and a range of ASF concentrations ([Fig. 3](#F3){ref-type="fig"}*A*), precipitates were clearly detected already at \<0.1 μ[m]{.smallcaps} ASF in the presence of 2 or 5 μ[m]{.smallcaps} galectin-3 and then increased in amount to reach a peak at about 1 and 4 μ[m]{.smallcaps} ASF, respectively, and finally, precipitate formation was inhibited at higher ASF concentrations. With fixed ASF concentrations and increasing concentrations of galectin-3 ([Fig. 3](#F3){ref-type="fig"}*B*), precipitates started to be detected at about 2 μ[m]{.smallcaps} galectin (with 0.8 and 4 μ[m]{.smallcaps} ASF) or about 8 μ[m]{.smallcaps} (with 20 μ[m]{.smallcaps} ASF) galectin and then continued to increase in amount without reaching a maximum. At the highest galectin-3 concentration tested, the molar ratio to ASF was about 60, 25, and 7 for the three concentrations used (0.8, 4, and 20 μ[m]{.smallcaps}, respectively). These data are consistent with the data from the FA assay. Excess ASF will compete for the carbohydrate recognition site of galectin-3 and inhibit the type-C self-association, but with excess galectin-3, more and more aggregates are formed without sign of reaching saturation. The formation of precipitates was also detected at the same conditions as described above by dynamic light scattering, and their size increased over a small galectin concentration range and then remained a few μm in diameter ([supplemental Fig. S3](http://www.jbc.org/cgi/content/full/C112.358002/DC1)). The precipitates did not confound FA analysis by the experimental criteria shown before for galectin-1 ([@B16]), as described in the legend for [supplemental Fig. S4](http://www.jbc.org/cgi/content/full/C112.358002/DC1).

![**Detection of galectin-3-ASF precipitates.** *A*, fixed concentrations of galectin-3 (2 and 5 μ[m]{.smallcaps}) were mixed with a range of concentrations of ASF. *B*, fixed concentrations of ASF (0.8 μ[m]{.smallcaps} (*broken lines*) or 20 μ[m]{.smallcaps} (*unbroken lines*) were mixed with a range of concentrations of galectin-3. Absorbance (*Abs*) was measured at 350 nm (*y* axes), at room temperature within 10 min. Background (∼0.2), mainly due to the plate, was subtracted. Absorbance due to the components of the samples measured separately was \<0.02.](zbc0281213070003){#F3}

#### Requirements for Type-C Galectin-3 Self-association

Analysis of galectin-3 with 180 μ[m]{.smallcaps} LacNAc, corresponding to the maximum number of LacNAc residues in 20 μ[m]{.smallcaps} ASF, gave no sign of self-association but had a binding curve consistent with a simple 1:1 interaction ([Fig. 2](#F2){ref-type="fig"}*G*) and no precipitate. LNnH, a branched glycan with two terminal LacNAc residues, also did not induce any sign of type-C self-association in the FA assay ([Fig. 2](#F2){ref-type="fig"}*H*), but galectin-3 bound it consistent with two saturable binding sites having *K~d~* of about 20 μ[m]{.smallcaps} in agreement with published data ([@B21]). This saccharide, however, formed precipitates with high galectin concentrations (over ∼100 μ[m]{.smallcaps} galectin-3 and \>∼25 μ[m]{.smallcaps} of the saccharide, not shown) as reported for a similar branched saccharide ([@B8]) and proposed to be due to type-N self-association. Thus, some particular feature of ASF as compared with its component galectin-binding sites was required to induce the type-C self-association of galectin-3 detected by the FA assay.

To examine this further, we analyzed a galectin-3 mutant, R186S, that modifies the carbohydrate recognition site but does not destroy it. It has strongly reduced affinity for LacNAc ([@B17]) and \>30-fold reduced affinity for ASF, calculated from the inhibition curve as for wild type galectin-3 (not shown), but can still be analyzed by the FA assay because it has retained affinity for the lactose-based probes. This showed that despite the lack of inhibition by ASF, a strong apparent type-C self-association was induced ([Fig. 2](#F2){ref-type="fig"}*I*), and free galectin concentration appeared to approach a limit, as for galectin-3 WT but higher (about 30 μ[m]{.smallcaps}). Surprisingly, this mutant also formed precipitates in the presence but not absence of ASF, but this required much higher galectin concentration as compared with galectin-3 WT ([Fig. 3](#F3){ref-type="fig"}*B*, *unfilled symbols*). Precipitates started to be detected at ∼20--70 μ[m]{.smallcaps} galectin, but in contrast to galectin-3 WT, lower ASF required more galectin for precipitation to start, possibly because now glycans on ASF are not competing with the self-association. At the highest galectin-3 R186S concentration tested, the molar ratio to ASF was about 250, 50, and 4 for the three concentrations used (0.8, 4, and 20 μ[m]{.smallcaps}, respectively). Thus, ASF-induced nucleation of galectin-3 type-C self-association occurs even with low or no binding to glycans, as shown with R186S, but is much more efficient and occurs at much lower galectin concentration if higher affinity glycan binding also occurs, as with galectin-3 WT.

Galectin-3C showed no precipitate with ASF ([supplemental Fig. S3](http://www.jbc.org/cgi/content/full/C112.358002/DC1)), but the FA assay showed evidence for type-C self-association with excess binding over the level of theoretical glycan-binding sites and the concentration of free galectin approaching a constant level (∼20 μ[m]{.smallcaps})([Fig. 2](#F2){ref-type="fig"}*J*). Thus, galectin-3C also appears to be able to associate with itself, as has been proposed ([@B11]), but much less efficiently as compared with intact galectin-3, and as expected from previous studies ([@B3], [@B9], [@B10]), it shows no ability to cross-link the ligand.

#### Galectin-3 Self-association at Cell Surface

Analysis of galectin-3 binding and uptake by a macrophage cell line provided evidence for type-C self-association at the cell surface. Preincubation with low (1 μ[m]{.smallcaps} (Ref. [@B18]) or high (5 μ[m]{.smallcaps} ([supplemental Fig. S5](http://www.jbc.org/cgi/content/full/C112.358002/DC1))) galectin-3 strongly enhanced uptake of subsequently added 0.2 or 2 μ[m]{.smallcaps} fluorescein-labeled galectin-3, respectively. Thus, galectin-3 enhances its own cell surface binding and uptake at physiological concentration and even up to 5 μ[m]{.smallcaps} range without sign of saturation. If galectin-3 binding approached saturation of glycan ligands, as is likely to occur without self-association or with type-N self-association, one would expect that the preincubation with high galectin-3 would reduce the binding of subsequently added galectin-3.

DISCUSSION
==========

The type-C self-association of galectin-3 proposed here ([Fig. 1](#F1){ref-type="fig"}*B*) is consistent with most previously published data but not with many interpretations. The key feature, that one galectin-3 CRD can bind another by a mechanism that engages the carbohydrate-binding site, was experimentally demonstrated by Yang *et al.* ([@B11]), but their model of CRD-dimer formation, with the carbohydrate-binding sites facing each other, would prevent oligomer formation. However, their data also agree with the model in [Fig. 1](#F1){ref-type="fig"}*B*, where the carbohydrate-binding site of one CRD binds at the other side of the next CRD, and the finding of CRD trimers by electron microscopy ([@B13]) supports the possibility of oligomer formation. The N-terminal domains of galectin-3 are not required for type-C self-association ([Fig. 2](#F2){ref-type="fig"}*J*), but they clearly enhance it ([Fig. 2](#F2){ref-type="fig"}*C*) (and are required for the concomitant aggregation with ligands as discussed below). Despite this enhancement, type-C self-association is not efficient for galectin-3 by itself in solution as it was captured only at low level by chemical cross-linking (Fig. 4 in Ref. [@B11]) and not detected by DLS for \<100 μ[m]{.smallcaps} galectin ([supplemental Fig. S1](http://www.jbc.org/cgi/content/full/C112.358002/DC1)).

Efficient type-C self-association also needs a step of initiation or nucleation, here triggered by ASF in solution ([Fig. 2](#F2){ref-type="fig"}, *C*, *E*, and *F*), but not by small saccharides ([Fig. 2](#F2){ref-type="fig"}, *G* and *H*). How this makes galectin-3 more prone to self-association remains unknown, but different orientations of the N-terminal domains relative to the CRD have been proposed ([@B8], [@B10]--[@B13]). The nucleation can occur even without (or with very weak) initial binding to a β-galactoside-containing glycan, as seen, albeit less efficiently, with the R186S mutant ([Fig. 2](#F2){ref-type="fig"}*I*). This may explain lactose-inhibitable binding of galectin-3 to some non-galactoside-containing ligands ([@B22]--[@B24]) if the lactose blocked the CRD-CRD interaction rather than the initial binding to the ligand.

Efficient nucleation followed by type-C self-association is consistent with the binding of galectin-3 to surface-immobilized laminin and other glycoproteins with apparent positive cooperativity and without saturation ([@B9], [@B10], [@B12], [@B15]), but contradicts the suggestion that galectin-3 binds to ASF in solution with negative cooperativity ([@B19]). It may agree, however, with the isothermal titration calorimetry in Ref. [@B19] if galectin-galectin interaction contributed to the heat release as ASF was titered into galectin-3 (34 μ[m]{.smallcaps}), the most for the early injections when the galectin was in excess over ASF.

Different variants of type-N self-association ([Fig. 1](#F1){ref-type="fig"}*A*) have been suggested to induce ligand cross-linking by galectin-3 because the N-terminal domains are required for glycoprotein precipitation, cell agglutination, the positive cooperative binding described above, and other effects ([@B3], [@B6]). These models are supported by the tendency of the N-terminal domains to aggregate by themselves, *e.g.* into filaments ([@B13]), but there is no other direct evidence for these models. The same aggregation tendency could in fact explain ligand cross-linking by type-C self-association, now between multiple N-domains exposed as part of galectin-3 oligomers. In either model, the details of the galectin-ligand complex structure remain unknown. Experimentally, the two models can be distinguished if fixed ligand concentration is titered with increasing galectin concentration; excess galectin is expected to saturate binding sites and inhibit complex formation for the type-N model as for classical antibody-antigen complexes, but not for the type-C model as found here with ASF in solution ([Figs. 2](#F2){ref-type="fig"}, *C*, *E*, and *F*, and [3](#F3){ref-type="fig"}*B*) and with glycoprotein-coated surfaces ([@B9], [@B10], [@B12], [@B15]). The two models cannot be distinguished if fixed galectin concentration is titered with increasing ligand concentration (*e.g.* [Figs. 3](#F3){ref-type="fig"}--4 in Ref. [@B8]) because excess ligand would inhibit complex formation in the classical way for both models and also by interfering with the CRD-CRD interaction of type-C model ([Fig. 3](#F3){ref-type="fig"}*A*).

It remains to be determined whether and when either model in [Fig. 1](#F1){ref-type="fig"} (or a mixture of them) occurs in cellular systems; the analysis of galectin-3 interaction with itself at the cell surface by fluorescence resonance energy transfer (FRET) ([@B14]) is consistent with both. The type-C model will be favored when there is a sufficiently potent nucleating ligand and the local concentration of galectin-3 exceeds the local concentration of competing galactosides, as shown in [Fig. 3](#F3){ref-type="fig"} and described above. The low concentrations of galectin-3 (μ[m]{.smallcaps}) and the model glycoprotein ASF (\<1 μ[m]{.smallcaps}) required make it plausible that it will occur in cellular systems, also supported by the promotion of galectin-3 cell surface binding by itself ([supplemental Fig. S5](http://www.jbc.org/cgi/content/full/C112.358002/DC1)) ([@B18]). It may be particularly favored in the cytosol and nucleus where no competing galactosides have been found, provided that there is a potent enough nucleating ligand, and perhaps contribute to galectin-3 interaction with, for example, K-Ras as part of nanoclusters ([@B24]) or Bcl-2 ([@B22]). A special case may be the very rapid accumulation of cytosolic galectin-3 around phagosomes lysed by bacteria ([@B25]); the exposure to glycoproteins normally inside the phagosome may nucleate type-C self-association as a defense and/or membrane repair signal.

Type-C self-association provides an interesting new framework to interpret galectin-3 function and suggests new lines of investigation. One is more detailed molecular analysis of galectin-3 self-association, and in particular, identification of the binding site on the back of the CRD. Another is identification of new proteins with the potency to initiate type-C self-association of galectin-3 and more detailed analysis of the determinants required for this.
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